Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.
Clene Nanomedicine has raised $7.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
Clene Nanomedicine's investors include Vivo Capital, National Institutes of Health, Coastlands Capital, Boxer Capital, National Multiple Sclerosis Society (NMSS).
Clene Nanomedicine is headquartered in Salt Lake City, United States.
Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.
Clene Nanomedicine is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Clene Nanomedicine — Funding & Investors." VCBacked, May 5, 2026, https://www.vcbacked.co/company/clene-nanomedicine. Accessed July 19, 2026.
VCBacked. (2026). Clene Nanomedicine — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/clene-nanomedicine
{{cite web |title=Clene Nanomedicine — Funding & Investors |url=https://www.vcbacked.co/company/clene-nanomedicine |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated